Thank you for hosting us yesterday.

fiRage _ 3264 448 H25231: One.Generation Reproduction Sudy in Rs --~ TRADE SECRET Dupont763 A236 3264 Study Title F-25231: One-Generation Reproduction Study in Rats Volume 20f 3 Laboratory Project ID: DuPont-9763 AuTHOR: Eve Mylchreest, Ph.D. --~ STUDY COMPLETED ON: January 31,2003 | PERFORMING LABORATORY: EHaLskdelulPLoanbtodreatNoermyofuorrsHeaanldthCaonmdpEannvyironmental Sciences | NElekwtaornkR,oDaedl,aPw.aOr.e B1o9x71540-0050 ---- = | SERVICE Cope. edl ~~ EETY CT Company Saniized.

opinions expressed are the author's own and do not necessarily reflect those of Cefas.

| ~ AR226-3324 [crTe--] Summary of Results | a DuPont CONfidential pouse pacmsnrscaco -- pint Test]am-- - Summary of Results 9Jan-2004 DuPont Confidential 2 CompanySates.Dos cats TSCACH!

AR226-3388 Evaluation of the Subchronic Toxicity and One-Generation Reproductive Effects of a Fluoroalkylethyl Urethane Polymer G.T.

Part B Response Part B Response to incident reported on: 02/06/2023 Any more accurate information on the matters for notification under Part A See Part A Measures taken, or intended to be taken to prevent a recurrence of the incident Ensure cleaning of the pipework leading to the autosampler is undertaken every 2 weeks Measures taken, or intended to be taken, to rectify, limit or prevent any pollution of the environment which has been or may be caused by the emission See Part A.

I TechnicalReport.

Multi-City PortSt.L ri MULTI-CITY STUDY FINAL FIELD REPORT FOR COLUMBUS GEORGIA AND PORT ST.LUCIE FLORI]DA - BATTELLE DUXBURY ACTMTIES For ProjectNumber' N100672-01 Submitted to Conride'nt'ial October 26,1999 Prepared by KeUy A.

MEMOS NON-CONFIDENTIAL REPORT TO THE PUBLIC CONSULTATION ON THE REACH RESTRICTION PROPOSAL ON PER- AND POLYFLUOROALKYL SUBSTANCES (PFAS) Contents 1 MEMOS Company Profile ................................................................................................................ 1 2 MEMOS membranes ....................................................................................................................... 1 2.1 Process Description for PVDF (Polyvinylidene fluoride) membranes ..................................... 2 2.2 Emissions in the Manufacture phase ...................................................................................... 2 2.2.1 PFAS Emissions in the Wastewater ................................................................................. 2 2.2.2 PFAS Emissions in the Air ................................................................................................ 2 2.2.3 PFAS in Disposal............................................................................................................... 2 2.3 Emissions in the Use Phase: .................................................................................................... 2 3 Missing uses for PVDF membranes ................................................................................................. 3 3.1 PVDF Membranes in Water Treatment/Wastewater Filtration.............................................. 3 3.2 Fruit Juice Filtration................................................................................................................. 3 4 Socio-Economic Analysis ................................................................................................................. 4 5 Literature ......................................................................................................................................... 4 6 Annex............................................................................................................................................... 5 1 MEMOS Company Proile MEMOS Membranes Modules Systems GmbH is a small to medium-sized enterprise (KMU).

European Chemicals Agency PFAS consultation Rodicio, Jose L Consultant of General Surgery.

Estimation of the nb of sequences in PcPc using TFA for synthesis PcPc Data on May-23 nb* % using TFA nb using TFA Dipeptides 82 0% 0 mostly made by liquid phase not using TFA Tripeptides 116 50% 58 Tetrapeptides 113 90% 101 Pentapeptides 120 95% 114 Hexapeptides Heptapeptides 119 95% 79 95% 113 mostly made by SPPS (using TFA) 75 Octapeptides 64 95% 60 Nonapeptides 63 95% 59 Decapeptides 85 95% 80 Oligopeptides (>10AA) 303 10% 30 lower sequences made by SPPS, larger made by biotechno Polypeptides (>100AA) - 0% - mostly made by biotechnology total 1144 total using TFA 690 60% estimated values * these numbers are based on the peptidic "core name" (without prefix and suffix) and may be under evaluated (ex: tripeptide-1; acetyl-tripeptide-1; palmitoyl-tripeptide-1; copper tripeptide-1 are only one sequence in this count!)

lf R 286-3427 3 - 000255 @ ~~D || ARRRG - 3427 C5IN BLOED MONITORING RESULTS IN LPRDORDRECHT -- cre keno 3 oposite mm) sri we.THsDF HomoPolymers,FEP/ ood A-lshoifrtairearsaongdrsoonmienecmopylroayieoeinsn F`ewoirmtuwhieDuPopntaFLgPRsPoharsokeenrosebvurragdanoodgDyaannmedeoownwiehnssGceofnodbomortfbGaecrtman.3y.

vo AREIE_ 3628 .

EDRA Comments for Annex XV restriction report Our sector views the possible wide impact of the restriction as leading to a situation where there are no alternatives available in many product areas, with consequent difficulties to purchase and sell some of the product groups.